Target Name: NAALADL1
NCBI ID: G10004
Review Report on NAALADL1 Target / Biomarker Content of Review Report on NAALADL1 Target / Biomarker
Other Name(s): 100 kDa ileum brush border membrane protein | NAALADASEL | peptidase homolog | human ileal aminopeptidase | ileal peptidase I100 | N-acetylated-alpha-linked acidic dipeptidase-like protein | Aminopeptidase NAALADL1 | ileal dipeptidylpeptidase | NALDL_HUMAN | NAALADase L | N-acetylated alpha-linked acidic dipeptidase like 1 | HILAP | Ileal dipeptidylpeptidase | I100

What is NAALADL1?

NAALADL1, also known as N-acetylated alpha-linked acidic dipeptidase-like 1, is a protein that functions as a drug target and biomarker in various diseases. It is an important member of the NAALADase enzyme family and plays a crucial role in several physiological processes. In this article, we will discuss the significance of NAALADL1 as a drug target and biomarker, its structure, and its potential applications in the field of medicine.

Structure of NAALADL1

NAALADL1 is a type II integral membrane protein that consists of 750 amino acids. It contains a transmembrane domain and a cytosolic domain. The extracellular domain of NAALADL1 has a conserved glutamate-binding motif which is crucial for its enzymatic activity.

The Role of NAALADL1 in Diseases

NAALADL1 has been implicated in various diseases, making it an attractive drug target and biomarker. One of its well-known associations is with prostate cancer. NAALADL1 expression has been found to be significantly upregulated in prostate cancer tissues compared to normal prostate tissues. Studies have shown that NAALADL1 overexpression promotes cancer cell growth and invasion. Therefore, targeting NAALADL1 could potentially be a therapeutic strategy for prostate cancer treatment.

In addition to prostate cancer, NAALADL1 has also been implicated in other types of cancer. It has been found to be overexpressed in colorectal cancer, lung cancer, and ovarian cancer. This suggests that it may serve as a common biomarker in multiple cancer types, allowing for the development of targeted therapies.

NAALADL1 as a Drug Target

Targeting NAALADL1 has gained significant attention in drug discovery research. Various small molecule inhibitors have been developed to specifically target NAALADL1, aiming to inhibit its enzymatic activity or disrupt its protein-protein interactions. These inhibitors have shown promising results in preclinical studies in different cancer models.

One of the strategies to target NAALADL1 is to develop peptidomimetic compounds that can bind to the glutamate-binding motif of NAALADL1 and inhibit its enzymatic activity. By blocking NAALADL1's catalytic function, these compounds can potentially halt cancer cell proliferation and invasion.

Another approach is to disrupt the protein-protein interactions involving NAALADL1. This can be achieved by developing small molecule inhibitors that can bind to the surface of NAALADL1 and prevent its interaction with other proteins, ultimately inhibiting downstream signaling pathways.

Potential Applications in Medicine

The understanding of NAALADL1's role in diseases and its structure has opened up new possibilities for diagnostic and therapeutic applications. NAALADL1 expression levels can serve as a biomarker for various cancers, making it a potential diagnostic tool for early detection and monitoring of disease progression.

Moreover, NAALADL1-targeted therapies hold promise as a novel treatment modality for cancer. These therapies can be used alone or in combination with existing treatments to improve efficacy and minimize side effects. The development of targeted therapies specific to NAALADL1 allows for personalized medicine, where treatment can be tailored to the individual's genetic makeup and disease characteristics.


NAALADL1 is an important protein with significant implications in various diseases, particularly cancer. Its structure and functional roles make it an attractive drug target and biomarker. The development of NAALADL1-targeted therapies not only holds promise for cancer treatment but also opens up avenues for personalized medicine. Further research and development in this area are essential to fully harness the potential of NAALADL1 in improving patient outcomes and advancing the field of medicine.

Protein Name: N-acetylated Alpha-linked Acidic Dipeptidase Like 1

Functions: Aminopeptidase with broad substrate specificity. Has lower activity with substrates that have Asp or Glu in the P2' position, or Pro in the P3' position. Lacks activity with substrates that have both Pro in the P3' position and Asp or Glu in the P2' position (PubMed:25752612). Lacks carboxypeptidase activity. Lacks dipeptidyl-peptidase IV type activity (PubMed:25752612)

The "NAALADL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NAALADL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

NAALADL2 | NAALADL2-AS3 | NAB1 | NAB2 | NABP1 | NABP2 | NACA | NACA2 | NACA3P | NACA4P | NACAD | NACC1 | NACC2 | NAD(P)H dehydrogenase, quinone | NAD-Dependent Protein Deacetylase | NADH dehydrogenase (Complex I) | NADK | NADK2 | NADPH Oxidase | NADPH Oxidase Complex | NADSYN1 | NAE1 | NAF1 | NAG18 | NAGA | NAGK | NAGLU | NAGPA | NAGPA-AS1 | NAGS | NAIF1 | NAIP | NAIPP2 | NALCN | NALCN sodium channel complex | NALCN-AS1 | NALF1 | NALF2 | NALT1 | NAMA | NAMPT | NAMPTP1 | NANOG | NANOGNB | NANOGP1 | NANOGP8 | NANOS1 | NANOS2 | NANOS3 | NANP | NANS | NAP1L1 | NAP1L1P1 | NAP1L2 | NAP1L3 | NAP1L4 | NAP1L4P1 | NAP1L5 | NAP1L6P | NAPA | NAPA-AS1 | NAPB | NAPEPLD | NAPG | NAPRT | NAPSA | NAPSB | NARF | NARS1 | NARS2 | Nascent polypeptide-associated complex | NASP | NAT1 | NAT10 | NAT14 | NAT16 | NAT2 | NAT8 | NAT8B | NAT8L | NAT9 | NATD1 | Natural cytotoxicity triggering Receptor | NAV1 | NAV2 | NAV2-AS5 | NAV2-AS6 | NAV3 | NAXD | NAXE | nBAF complex | NBAS | NBAT1 | NBDY | NBEA | NBEAL1 | NBEAL2 | NBEAP1 | NBEAP3 | NBL1